tirzepatide press release Breaking FDA Approves Tirzepatide, A Potential

We need better evidence on how these medications work and what to do after stopping, such as how to transition care and what kinds of lifestyle and psychological support help to maintain benefits. The new research comes at a time when access to, and interest in, weight-loss medications is rapidly expanding across the globe

in Cardiology/Journal Scans/2025/07/10/09/09/SURMOUNT 5 Mamas, M.A., Bays, H., et al

Ipamorelin, a selective pentapeptide growth hormone secretagogue derived from GHRP-1, was originally developed by Novo Nordisk and represents the first highly selective growth hormone-releasing peptide with minimal effects on other pituitary hormones

However, the practical impact depends on the specific supplement and the underlying physiology of the individual

You deserve a weight loss journey that leaves you stronger, not weaker